null

null

null

null

null

null

null

null

null

0.45x Total Debt / Equity (Conservative)

Minimal floating-rate debt exposure; pre-revenue clinical-stage company primarily equity-funded, so 200bps rate rise modestly increases cost of future debt financing

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Single-source medical-grade hollow-fiber membrane components (likely Asia-based) and specialized biocompatible tubing; FDA-regulated device manufacturing concentration

Negligible current international revenue; CE Mark pursuit underway but no material foreign currency exposure yet—USD-denominated operations only

Effectively 100% US-based revenue; no material sovereign currency devaluation exposure given domestic-only commercial operations at this stage

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High; SCD (Selective Cytopheretic Device) relies on single-source hollow-fiber cartridge manufacturer, representing non-substitutable critical component with no disclosed backup supplier

Medical device hardware manufacturer; cloud infrastructure dependency is minimal—operational disruption from cloud termination would be administrative, not product-delivery-critical

Regulatory submission and clinical data management secondarily cloud-dependent; 30-day termination would delay FDA correspondence workflows but not halt device production

Low API coupling risk; company uses standard EHR/hospital interfaces, not proprietary API ecosystems—switching cost is regulatory revalidation of device, not software integration

Low Howey risk; revenue model is FDA-cleared medical device sales—straightforward product transaction, not an investment contract or profit-sharing scheme

Very High

Low current exposure; limited patient data handled directly, though HIPAA is primary compliance framework; GDPR exposure minimal until EU commercial launch

Low; niche acute kidney injury device market with no dominant market share; no bundling or exclusivity practices flagged by regulators

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Effectively 0% recurring/subscription revenue currently; 100% transactional per-device or per-use hospital sales model anticipated at commercialization

Per-procedure disposable device revenue model; each SCD treatment generates single-use cartridge sale to hospital or ICU setting

Cost-plus pricing tied to hospital reimbursement (CPT/DRG codes); vulnerable if CMS reimbursement rates compress or payer coverage decisions lag FDA approval

Moderate; life-saving indication supports premium pricing, but hospital formulary committees and group purchasing organizations (GPOs) cap realized pricing power—est. $2,000–$5,000 per treatment

95.7% Gross Margin (Premium (>60%))

No free-rider problem; device requires physician prescription and hospital procurement—no alternative free pathway exists for the therapeutic indication

Growth is partially headcount-sublinear; manufacturing scale drives COGS, but sales force expansion (hospital-by-hospital adoption) is headcount-linear in early commercialization phase

Moderate marginal cost; disposable cartridge manufacturing has scale economies, but each new hospital account requires dedicated clinical specialist support and capital equipment placement

Not applicable; company does not operate a franchise model

At 10x scale, CAC economics improve modestly via GPO contracts but remain constrained by hospital budget cycles; estimated CAC recovery requires ~10–15 procedures per account

Weak network effects; clinical outcome data accumulation strengthens reimbursement and physician adoption, but no direct user-to-user network dynamic exists

-85.8% Return on Assets (Negative equity)

Tier 2 moderate resilience; acute kidney injury in ICU settings is non-discretionary, but hospital capital budget freezes during recessions can delay device adoption and capital placements

ICU/critical care physicians and hospital systems treating acute kidney injury and sepsis patients; high concentration risk with limited number of Level 1 trauma/academic medical centers

Nephrology departments and dialysis-adjacent hospital units; secondary segment broadens addressable base but faces same formulary and reimbursement gatekeeping challenges

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital being deployed toward FDA Breakthrough Device commercialization and manufacturing scale-up; no legacy infrastructure reallocation—greenfield capex model with high burn relative to revenue

0001831868

ICU